RESUMO
Objective@#To explore the effects of cinobufagin capsule on coagulation status, therapeutic effect and quality of life of patients with advanced lung cancer.@*Methods@#A total of 64 patients with advanced lung cancer admitted to the Second People's Hospital of Jinzhong from February 2017 to January 2018 were selected, and they were divided into control group and observation group by random number table method, with 32 cases in each group.The control group was treated with chemotherapy, and the observation group was treated with cinobufagin capsules combined with chemotherapy.Blood coagulation status, quality of life score, pain numerical rating scale (NRS) and functional status score(KPS) were observed before and after treatment in the two groups.The clinical efficacy was compared between the two groups.@*Results@#Before treatment, there were no statistically significant differences in plasma fibrinogen(FIB), platelet(PLT), D-dimer, quality of life score, NRS score and KPS score between the two groups(all P>0.05). After treatment, the FIB, PLI and D-dimers in the observation group were (3.6±0.9)g/L, (248.3±11.3)×109/L, (19.8±1.2)mg/L respectively, which were significantly lower than those in the control group [(4.5±0.6)g/L, (398.2±16.2)×109/L, (40.2±0.6)mg/L] (t=11.642, 21.045, 18.249, all P<0.05). The total effective rate of the observation group was 90.6%(29/32), which was significantly higher than 68.8%(22/32) of the control group(χ2=6.903, P<0.05). The quality of life scores of the two groups were improved, and the life scores of the observation group were significantly higher than those of the control group(t=11.642, 21.045, 18.249, 17.218, all P<0.05). The NRS score of the observation group (3.62±1.53)points was significantly lower than that of the control group[(5.01±2.34)points], and the KPS score of the observation group[(78.25±3.81)points] was significantly higher than that of the control group[(72.34±4.12)points], the differences were statistically significant (t=16.082, 15.082, all P<0.05).@*Conclusion@#Treatment of advanced lung cancer with cinobufagin capsule combined with chemotherapy can significantly improve the coagulation state, treatment effect and quality of life of patients.
RESUMO
To evaluate the effectiveness and safety of Huachansu in the treatment of cancer-related pain,four Chinese databases( CNKI,VIP,Wan Fang,Sino Med) and three English databases( Cochrane Library,Medline,PubMed) were systematically and comprehensively retrieved since the establishment of each database to October 2018. Randomized controlled trials( RCTs) for the treatment of cancer-related pain with Huachansu were screened out according to pre-established inclusion criteria and exclusion criteria. Rev Man5. 3 software was used for Meta-analysis. A total of 241 articles were retrieved,and finally 10 studies were included. The total sample size was 1 293,including 648 in the experimental group and 645 in the control group. The overall quality of the included studies was generally low. The results of Meta-analysis showed that Huachansu combined with Western medicine acesodynes was superior to the single use of Western medicine acesodynes in the treatment of short-term pain relief,improvement of quality of life and reduction of constipation,nausea and vomiting,dizziness,drowsiness,anorexia and other adverse reactions. And it also has the advantage of a shorter onset time and longer duration time of analgesia,but cannot reduce the incidence of dysuria. Based on the findings,Huachansu had a certain effect in the treatment of cancer-related pain,and a significant positive effect on the improvement of quality of life and the reduction of adverse reactions. No serious adverse reactions occurred. However,due to the small number of studies included,the low quality of the included studies,published biases and other restrictions,the evidence in this study has a low quality,and the conclusion shall be adopted with caution. The effectiveness and safety of Huachansu in the treatment of cancer-related pain remained to be further confirmed in the future with a well-designed,rigorous,and standardized report,with a large sample size,multiple centers,and sufficient follow-up time for randomized controlled trials.
Assuntos
Humanos , Venenos de Anfíbios , Usos Terapêuticos , Dor do Câncer , Tratamento Farmacológico , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Objective To explore the effects of cinobufagin capsule on coagulation status,therapeutic effect and quality of life of patients with advanced lung cancer.Methods A total of 64 patients with advanced lung cancer admitted to the Second People＇s Hospital of Jinzhong from February 2017 to January 2018 were selected,and they were divided into control group and observation group by random number table method,with 32 cases in each group.The control group was treated with chemotherapy, and the observation group was treated with cinobufagin capsules combined with chemotherapy.Blood coagulation status,quality of life score,pain numerical rating scale ( NRS) and functional status score( KPS) were observed before and after treatment in the two groups.The clinical efficacy was compared between the two groups. Results Before treatment, there were no statistically significant differences in plasma fibrinogen(FIB),platelet(PLT),D-dimer,quality of life score,NRS score and KPS score between the two groups(all P>0.05).After treatment,the FIB,PLI and D-dimers in the observation group were (3.6 ± 0.9)g/L, (248.3 ± 11.3) ×109/L,(19.8 ± 1.2) mg/L respectively,which were significantly lower than those in the control group [(4.5 ± 0.6)g/L,(398.2 ± 16.2) ×109/L,(40.2 ± 0.6) mg/L] (t=11.642,21.045,18.249,all P＜0.05).The total effective rate of the observation group was 90.6%(29/32),which was significantly higher than 68.8%(22/32) of the control group ( χ2 =6.903,P ＜0.05). The quality of life scores of the two groups were improved,and the life scores of the observation group were significantly higher than those of the control group( t=11.642,21.045,18.249,17.218,all P＜0.05).The NRS score of the observation group (3.62 ± 1.53) points was significantly lower than that of the control group[(5.01 ± 2.34)points],and the KPS score of the observation group [(78.25 ± 3.81) points] was significantly higher than that of the control group [( 72. 34 ± 4. 12 ) points], the differences were statistically significant (t =16.082,15.082,all P ＜0.05). Conclusion Treatment of advanced lung cancer with cinobufagin capsule combined with chemotherapy can significantly improve the coagulation state, treatment effect and quality of life of patients.
RESUMO
Objective: To study the effect of intracavitary infusion of Huachansu injection combined with polysaccharide nucleic acid fraction of Bacillus Calmette Guérin (BCG-PSN) or cisplatin in the treatment of the malignant pleural and peritoneal effusions. Methods: Seventy patients were randomly divided into two groups. Patients in the treatment group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 18 mL of BCG-PSN; patients in the control group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 60 mg of cisplatin once a week and the treatment lasted for 2-4 weeks. Results: For the treatment group, the response rate (complete response + partial response) was 83.3% in 24 cases with malignant pleural effusion and 63.6% in 11 cases with malignant peritoneal effusion. The total response rate was 77.1% (27/35) in the treatment group. The KPS score was elevated in 26 cases, stable in 7 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 69.2% in 13 cases with malignant peritoneal effusion. The total response rate was 80.0% (28/35). The KPS score was increased in 16 cases, stable in 11 cases, and decreased in 8 cases. There was no significant difference in clinical efficacy between the two groups (P > 0.05). Patients in the treatment group had less adverse reaction and a more improved living quality than those in the control group (P < 0.05). Conclusion: Intracavitary infusion of Huachansu injection combined with BCG-PSN or cisplatin was effective in the treatment of malignant pleural and peritoneal effusions, but Huachansu injection plus BCG-PSN had less toxicity especially for the advanced patients who can not tolerate the intracavitary chemotherapy.
RESUMO
Objective: To observe the effect of intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites. Methods: The sixty six patients were randomly divided into two groups. Patients in the treatment group (n = 33) were infused with 20 mL of Huachansu injection and 60 mg of cisplatin intrapericardially once a week and the treatment lasted for 24 weeks. Patients in the control group (n = 33) were infused with 60 mg of cisplatin intrapericardially. Results: For the treatment group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 72.7% (8/11) in 11 cases with malignant ascites. The total response rate was 81. 8% (27/33). The living qualities were improved in 21 cases, stable in 10 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 52.4% in 21 cases with malignant pleural effusion and 41.7% in 12 cases with malignant ascites. The total response rate was 48.5%. The living qualities were improved in 9 cases, stable in 12 cases, and decreased in 12 cases. The response rate was significantly higher and the toxic reaction was significantly lower in the treatment group than that in the control group (P < 0.05). Conclusion: Intraperi-cardial infusion of Huachansu injection plus cisplatin achieves satisfactory effects in the treatment of malignant pleural effusion and ascites and has less side effects. It is worthy of clinical application.
RESUMO
Background and purpose:Huachansu has been widely used to treat cancer in China.But maximum tolerated dose(MTD) of huachansu is still not well defined.The purpose of this study was to conduct a Phase Ⅰ study to determine the MTD of huachansu in the treatment of patients with hepatocellular carcinoma,non-small cell lung or pancreatic cancer.Toxic profile and efficacy of huachansu were also assessed qualitatively.Methods:Huachansu was intravenously administered to patients with stage Ⅲ/Ⅳ hepatocellular carcinoma,non-small cell lung cancer,or pancreatic cancer.Each cycle consisted of daily huachansu for 14 days with an interval of 7 days between two cycles.2 or more cycles were delivered to the patients if no severe adverse event occurred.The planned dose escalation schedule for huachansu was as follows,10,20,40,60,90 and 120 ml/(m2?d).Results:Fifteen patients(3 at each level) have been recruited to the study(11 with hepatocellular carcinoma,2 with pancreatic cancer,and 2 with lung cancer).There were no dose limiting toxicities found after dose level 5.Among all these patients,the efficacy in 14 patients could be valued,in which,6 were SD(42.9%),8 were PD(57.1%).At dose level 1,there was one patient with hepatocellular carcinoma achieving a 20% reduction in tumor mass that lasted 11 months,6 of 15(42.9%) patients with stable disease and 8 of 15(57.1%) with progress disease after the treatment.Conclusions:To date,dose limiting toxicity has not been seen with doses up to eight times higher than that typically used before.Of interest, several patients had prolonged stable disease or minor tumor shrinkage.
RESUMO
Purpose:To study the synergistic inhibitory effects of huachansu plus vinorelbine on cell growth in mice bearing Lewis lung cancer. Methods:Fifty mice bearing Lewis lung cancer were randomly divided into control group,cyclophosphamide group (CTX),huachansu group (HCS), vinorelbine group (VNB) and huachansu plus vinorelbine group (HV). Each group included ten mice. Normal saline (0.2 ml),cyclophosphamide (30 mg/kg),huachansu (5 ml/kg),vinorelbine (6.7 mg/kg),huachansu (5 ml/kg) plus vinorelbine group (6.7mg/kg) were injected intraperitoneally,respectively in the five groups. After the drugs were administered for seven days,all mice were sacrificed and the tumors were weighed. The tumor inhibitory rates were calculated and compared among the five groups of mice. The growth cycles of Lewis lung cancer were analyzed with flow cytometry. Results:The tumor inhibitory rates of HCS,VNB and HV group were 42.86% ,45.68%,53.44%,respectively. The percentage of S phase of cell cycle was increased in HCS and the percentage of G 2 /M phase increased in VNB,and both increased in HV group. Conclusions:There exists synergistic inhibitory effect on Lewis lung cancer between huachansu and vinorelbine and the mechanisms could correlate with their synergistic effect on cell growth cycles.